Sjögren's disease & overlap diseases
Evaluating the therapeutic potential of tofacitinib in Sjögren’s disease: a comprehensive clinical and immunological assessment
Authors' conclusion
Tofacitinib effectively improves disease activity and immune regulation in SjD, and it is associated with suppressing Tfh and Tph cells, suggesting its potential as a treatment option.
Study context
- Population
- Patients diagnosed with Sjögren's disease (SjD)10 completed Cohort II
- Exposure
- Oral tofacitinib, before vs after treatment
- Cohort In = 112
- Outcome
- Change in disease activity (ESSDAI)
Methodological detailstwo independent cohorts, prospective (Cohort II)
- Two independent cohorts
- Prospective (Cohort II)
Main finding
As reported in the abstract
ESSDAI score, Cohort I, before vs after tofacitinib
Cohort I (baseline)
8.00
median · IQR 4.25–15.75
Cohort I (tofacitinib)
6.50
median · IQR 2.25–12.75
P < 0.001
Observational data: associations, not effects.
Further findings
ESSDAI score in Cohort II, vs baseline · sixth month
- Significant reduction in ESSDAI scores at the sixth month compared with baseline
- P = 0.001
- Ten patients completed the 12-month treatment period
ESSPRI decrease of at least one point or 15% in Cohort II
- Patients achieving a decrease of at least one point or 15% in ESSPRI scores
- 80% (8/10)
Proportion of Th17 cells in Cohort II
- Significant reduction in the proportion of Th17 cells (mean ± SD)
- 14.84 ± 7.70 vs 7.74 ± 4.24, P = 0.008
Tfh and Tph cells, pSTAT-3 in CD4+ T cells
- Decrease in Tfh and Tph cells, along with decreased pSTAT-3 levels in CD4+ T cells and disease activity scores
Safety
Serious adverse events
- None observed in the two cohorts
- 0
Original publication
Evaluating the therapeutic potential of tofacitinib in Sjögren’s disease: a comprehensive clinical and immunological assessment. Rheumatology (Oxford). Published 26 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →